How to Taper Off Sunosi (Solriamfetol) Safely

Can You Safely Taper Off Solriamfetol?

Yes, most people can stop taking solriamfetol safely, and the key is going gradually rather than stopping all at once. Cutting the dose down in steps over days to weeks gives your body time to adjust and lowers the chance of rebound sleepiness or mood dips hitting you hard. Your prescriber should be part of that plan from the start.

Solriamfetol works by blocking the reuptake of dopamine and norepinephrine (brain chemicals that promote wakefulness and focus). It is not a classic amphetamine and is not a federally controlled substance, but that does not mean stopping it is always symptom-free. The FDA label does not spell out a specific taper schedule, so the approach is tailored to you: your current dose, how long you have been taking it, and the reason you are stopping.

One important note: stopping cold turkey from higher doses (150 mg or 300 mg) is much more likely to cause significant rebound fatigue than stepping down from the starting 75 mg dose. The higher the dose, the more planned the exit should be.

What Withdrawal Symptoms Should You Expect?

The most common effect when stopping solriamfetol is rebound hypersomnolence (the return of heavy sleepiness that the medication was keeping in check). In the first few days, that sleepiness can feel more intense than it did before you ever started the medication. For most people, this peaks within one to three days and settles within one to two weeks.

Beyond sleepiness, you may notice:

• Low motivation or mild depression. More common after longer-term use, as dopamine activity adjusts.
• Irritability. Often mild and short-lived, but worth tracking.
• Increased appetite and fatigue. Typical stimulant discontinuation effects.
• Difficulty concentrating. Usually clears within the first week or two.

Severe psychiatric symptoms or prolonged insomnia are uncommon. If either occurs, contact your prescriber promptly rather than waiting it out.

What Does a Practical Taper Schedule Look Like?

Because solriamfetol comes in three tablet strengths (75 mg, 150 mg, and 300 mg), the dose steps are built into the available options. A common approach is to drop one step every five to seven days before stopping entirely.

The table below compares abrupt discontinuation to a gradual taper so you can see the tradeoffs clearly.

For patients on 300 mg, a two-step reduction (300 mg to 150 mg, then 150 mg to 75 mg, then stop) spread over two to four weeks is a reasonable framework. There is no strong evidence that tapering beyond four weeks adds meaningful benefit for solriamfetol specifically, though individual cases can vary.

One practical tip: time your final taper steps around lower-demand periods. Avoid high-pressure work weeks, long drives, or any stretch where you cannot afford to feel significantly sleepier than usual.

Why Are You Stopping? The Reason Shapes the Plan

The right exit strategy depends heavily on why you are discontinuing. A one-size-fits-all approach misses important variables.

• Switching to another wakefulness agent. Modafinil or pitolisant can often be started while solriamfetol is still stepping down, a strategy called cross-tapering, which reduces the gap in coverage.
• Pregnancy or planned pregnancy. Your provider may compress the timeline rather than extend it, prioritizing speed while monitoring closely.
• Side effects like elevated blood pressure or heart rate. A faster taper with cardiovascular monitoring may be warranted rather than a prolonged wind-down.
• The medication stopped working. Rebound effects still occur even when therapeutic benefit has faded, so a taper is still worthwhile.

If your underlying narcolepsy or obstructive sleep apnea (OSA) related excessive daytime sleepiness is not otherwise treated, stopping Sunosi without a replacement plan is a safety issue, not just a comfort question. Discuss this with your provider before beginning.

What Actually Helps During the Taper, and What Does Not?

Some strategies offer real, if modest, support during a solriamfetol taper. Others are widely tried but largely ineffective.

What may help:

• Consistent sleep schedule. A fixed wake time each day helps anchor your circadian rhythm (your internal body clock) and softens rebound sleepiness.
• Reducing light exposure at night. Screens and bright lighting after dark can make the sleep disruption worse.
• Staying physically active. Behavioral activation (keeping up with exercise and social commitments) counters low-motivation periods more effectively than resting passively.

What likely does not help enough:

• Strategic caffeine use. Caffeine is widely tried as a substitute but cannot replicate a wakefulness agent at therapeutic levels and often worsens nighttime sleep disruption.
• OTC energy and focus supplements. Products marketed with L-tyrosine stacks or similar ingredients lack clinical evidence for solriamfetol discontinuation specifically. The evidence is thin, and none have been tested against this withdrawal context.

One safety rule applies throughout the taper: restrict driving and operating heavy machinery until you know how rebound sleepiness is affecting you day to day. This is not optional caution.

When Should You Call Your Doctor Instead of Going It Alone?

Some taper situations need professional oversight, not just general guidance.

• Any taper from 150 mg or 300 mg should be supervised, given cardiovascular monitoring considerations at higher doses.
• Mood symptoms that worsen beyond mild irritability, especially any thoughts of self-harm, require immediate contact with your provider.
• Comorbid psychiatric conditions such as depression or ADHD place you at higher risk for significant discontinuation effects. A more closely monitored plan is not optional in these cases.
• No replacement treatment in place for narcolepsy or OSA-related excessive daytime sleepiness means stopping Sunosi carries functional and safety risks that need to be addressed before the first dose reduction.

Doctronic, the first AI legally authorized to practice medicine, offers 24/7 access to clinicians who can help you build a personalized taper schedule without a long wait. Video visits start at $39 and are HIPAA compliant, so you can get real clinical support on your timeline.

Frequently Asked Questions

How long does solriamfetol withdrawal last?

For most people, rebound sleepiness and mood changes peak within one to three days of the last dose and resolve within one to two weeks. Individual timelines vary based on dose, duration of use, and underlying condition.

Can I stop Sunosi suddenly if I am only on 75 mg?

Stopping from the lowest 75 mg dose carries less risk than stopping from higher doses, but rebound sleepiness can still occur. A brief step-down plan and provider awareness are still advisable before stopping entirely.

Does solriamfetol cause dependence or addiction?

Solriamfetol is not a controlled substance, but it can cause discontinuation effects including rebound fatigue and low mood. These differ from addiction, though a gradual taper helps minimize discomfort and safety risks.

Will my narcolepsy symptoms get worse when I stop Sunosi?

Yes, the excessive daytime sleepiness that Sunosi was treating will likely return, sometimes more intensely at first. Stopping without a replacement wakefulness plan in place is a safety concern your provider should address.

Can I taper solriamfetol and start modafinil at the same time?

Yes, cross-tapering is a common approach when switching wakefulness agents. Your prescriber can overlap the two medications strategically to reduce rebound sleepiness during the transition period.

The Bottom Line

Tapering off solriamfetol is manageable for most people when done gradually with a prescriber's guidance. Rebound sleepiness is the primary concern and can pose real safety risks, especially for driving or operating machinery, so planning ahead matters. The right taper speed depends on your dose, how long you have been on the medication, and why you are stopping. Doctronic offers 24/7 consultations, with over 22 million AI consultations completed and 99.2% treatment plan alignment with board-certified physicians, so you can get a personalized taper plan without a lengthy wait. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.